Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Welcure Drugs and Pharmaceuticals Ltd
Your Vote -
Buy
66.67%
Hold
22.22%
Sell
11.11%
66.67%
9 users have voted
Option Chain
Analyzes market sentiment, predicts Welcure Drugs and Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Welcure Drugs & - Announcement Pursuant To Regulation 32 Of SEBI (LODR) Regulations, 2015 - Non Applicability Of Filing State
-
Welcure Drugs & - Announcement under Regulation 30 (LODR)-Change in Management
-
Welcure Drugs & - Audited Standalone Financial Results And Audited Standalone Financial Statements Along With Auditor'S Repor
-
Welcure Drugs & - Board Meeting Outcome for Outcome Of Board Meeting
-
Welcure Drugs & - Board Meeting Intimation for For Consideration And Approval Of The Audited Financial Results\r\nFor The Qua
-
Welcure Drugs & - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Welcure Drugs & - Announcement under Regulation 30 (LODR)-Change in Management
-
Welcure Drugs & - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
-
Welcure Drugs & - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceutica
-
Welcure Drugs & - Board Meeting Intimation for Intimation Of Meeting Of The Board Of Directors Under The Regulation 29 Of The
-
Welcure Drugs & - Announcement under Regulation 30 (LODR)-Change in Management
-
Welcure Drugs & - Appointment of Company Secretary and Compliance Officer
-
Welcure Drugs & - Announcement under Regulation 30 (LODR)-Change in Management
-
Welcure Drugs & - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs &\r\nPharmaceut
-
Welcure Drugs & - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
-
Welcure Drugs & - Announcement under Regulation 30 (LODR)-Resignation of Managing Director
-
Welcure Drugs & has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Welcure Drugs & - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Key fundamentals
Evaluate the intrinsic value of Welcure Drugs and Pharmaceuticals Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 225.7094 | 1.341 | 1.5152 | 0.093 | 0.0694 |
| Liabilities | 225.7094 | 1.341 | 1.5152 | 0.093 | 0.0694 |
| Equity | 112.4391 | 13.439 | 13.439 | 12.1185 | 12.1186 |
| Gross Profit | 0.8778 | -0.232 | -0.1322 | 0.0235 | 0.0549 |
| Net Profit | 2.1701 | -0.174 | 0.1017 | 0.0235 | 0.0551 |
| Cash From Operating Activities | -222.0288 | -0.127 | 0.1068 | 0.0185 | 0.0422 |
| NPM(%) | 8.83 | 0 | 0 | 22.45 | 41.33 |
| Revenue | 24.55 | 0 | 0 | 0.105 | 0.1333 |
| Expenses | 23.6722 | 0.232 | 0.1322 | 0.0814 | 0.0784 |
| ROE(%) | 2.11 | -0.16 | 0.09 | 0.02 | 0.05 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Welcure Drugs and Pharmaceuticals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 859.90 | 1.12 | 28.38 | 6.53 | 301.39 | 0.58 |
| Lotus Eye Hospital and Institute Ltd | 72.27 | -2.54 | 205.89 | 23.79 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 26.00 | 1.13 | 0.00 | 49.40 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 806.15 | -0.38 | 0.00 | 22.43 | -687.10 | 0.00 |
Company Info
Welcure Drugs and Pharmaceuticals Limited (hereinafter referred to as 'The Company' or 'WDPL') was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992. The registered office of the Company is situated at E-1052. Saraswati Vihar, Delhi - 110 034. PRESENT BUSINESS Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups. The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals. The products of the company have already been well accepted in the domestic markets and the Company has an established customer base. SWOT ANALYSIS Strengths 1. One of the Promoters is having over two decades and the other two promoters are having over a decade experience in the pharmaceutical industry. 2. The Plant & Machinery taken by the company is a multipurpose plant on which other drugs can be produced apart from what company intends to manufacture. 3. The technolgy required to manufacture of the drugs is indegenously available. 4. Approval of first floor of factory by Drugs Control Department to systematically and properly utilise the space for expanded capacity. 5. Major portion of bulk drugs will be used for captive consumption for manufacture of pharmaceuticals formulations. 6. With the completion of the bulk drug unit, the Company will have integrated facilities to manufacture intermediates, bulk drugs and formulations. 7. Subsidiary Company A.K.Laboratories Ltd. is producing 6 APA, a critical drug intermediate used for manufacture of life saving antibiotic drugs like viz. Ampicillin, Amoxycillin, Cloxacillin and Cephalexin. Weaknesses 1. Commercial production of the existing formulation unit was delayed by five months and bulk drug unit is expected to be delayed by approximately 18 months. 2. The cost of the project and means of finance have not been appraised by any Bank/Financial Institution. 3. Delay in Government approvals may affect the timely implementation of the project. Opportunities 1. Products have a growing domestic market and good export potential. Threats 1. Competition from existing and proposed manufacturers as is normal and prevalent in any industry. 2. Changes in Drug Policy announced by the Government from time to time may have an impact on the operations of the Company. 2008 -Welcure Drugs & Pharmaceuticals Ltd has designated E-mail ID for Investors Complaints - welcure@gmail.com.
Welcure Drugs and Pharmaceuticals Limited (hereinafter referred to as 'The Company' or 'WDPL') was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992. The registered office of the Company is situated at E-1052. Saraswati Vihar, Delhi - 110 034. PRESENT BUSINESS Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups. The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals. The products of the company have already been well accepted in the domestic markets and the Company has an established customer base. SWOT ANALYSIS Strengths 1. One of the Promoters is having over two decades and the other two promoters are having over a decade experience in the pharmaceutical industry. 2. The Plant & Machinery taken by the company is a multipurpose plant on which other drugs can be produced apart from what company intends to manufacture. 3. The technolgy required to manufacture of the drugs is indegenously available. 4. Approval of first floor of factory by Drugs Control Department to systematically and properly utilise the space for expanded capacity. 5. Major portion of bulk drugs will be used for captive consumption for manufacture of pharmaceuticals formulations. 6. With the completion of the bulk drug unit, the Company will have integrated facilities to manufacture intermediates, bulk drugs and formulations. 7. Subsidiary Company A.K.Laboratories Ltd. is producing 6 APA, a critical drug intermediate used for manufacture of life saving antibiotic drugs like viz. Ampicillin, Amoxycillin, Cloxacillin and Cephalexin. Weaknesses 1. Commercial production of the existing formulation unit was delayed by five months and bulk drug unit is expected to be delayed by approximately 18 months. 2. The cost of the project and means of finance have not been appraised by any Bank/Financial Institution. 3. Delay in Government approvals may affect the timely implementation of the project. Opportunities 1. Products have a growing domestic market and good export potential. Threats 1. Competition from existing and proposed manufacturers as is normal and prevalent in any industry. 2. Changes in Drug Policy announced by the Government from time to time may have an impact on the operations of the Company. 2008 -Welcure Drugs & Pharmaceuticals Ltd has designated E-mail ID for Investors Complaints - welcure@gmail.com.
Read More
Parent Organisation
Welcure Drugs & Pharmaceuticals Ltd.
Founded
06/08/1996
Managing Director
NSE Symbol
FAQ
The current price of Welcure Drugs and Pharmaceuticals Ltd is
The 52-week high for Welcure Drugs and Pharmaceuticals Ltd is
The market capitalization of Welcure Drugs and Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Welcure Drugs and Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Welcure Drugs and Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Welcure Drugs and Pharmaceuticals Ltd shares.
The CEO of Welcure Drugs and Pharmaceuticals Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
